Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TODD ADAM GERSTEN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1962408047
CMS profile
88583
Location
WELLINGTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,964.79

200 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,602.87 198
Consulting Fee $350.00 1
Education $11.92 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Scientific Affairs, LLC $350.00 1
AstraZeneca Pharmaceuticals LP $344.49 21
PFIZER INC. $283.51 16
Janssen Biotech, Inc. $201.58 13
Lilly USA, LLC $189.55 7
GENZYME CORPORATION $179.81 10
Amgen Inc. $171.55 9
Foundation Medicine, Inc. $160.51 1
Eisai Inc. $150.21 8
E.R. Squibb & Sons, L.L.C. $147.94 12
Celgene Corporation $145.83 8
Seagen Inc. $108.55 7
Genentech USA, Inc. $108.22 6
Dova Pharmaceuticals $92.68 6
Bayer HealthCare Pharmaceuticals Inc. $84.36 5
JAZZ PHARMACEUTICALS INC. $81.54 5
GlaxoSmithKline, LLC. $80.22 5
Astellas Pharma US Inc $75.26 4
Daiichi Sankyo Inc. $73.15 3
MorphoSys, US Inc. $71.11 4
Myriad Genetic Laboratories, Inc. $68.56 4
Alexion Pharmaceuticals, Inc. $61.08 4
Merck Sharp & Dohme Corporation $60.57 3
Taiho Oncology, Inc. $59.38 3
Incyte Corporation $57.89 3
Novartis Pharmaceuticals Corporation $53.01 3
Pharmacyclics LLC, An AbbVie Company $45.50 2
Takeda Pharmaceuticals U.S.A., Inc. $41.11 2
Ipsen Biopharmaceuticals, Inc $39.95 2
PUMA BIOTECHNOLOGY, INC. $37.49 3
Kyowa Kirin, Inc. $36.92 2
AbbVie Inc. $32.65 2
Karyopharm Therapeutics Inc. $31.67 2
ARRAY BIOPHARMA INC $31.46 2
Gilead Sciences, Inc. $31.14 2
Kite Pharma, Inc. $24.86 1
SUN PHARMACEUTICAL INDUSTRIES INC. $20.56 1
Regeneron Healthcare Solutions, Inc. $19.98 1
TG THERAPEUTICS, INC. $17.49 1
Rigel Pharmaceuticals, Inc. $16.41 1
SANOFI-AVENTIS U.S. LLC $16.13 1
Global Blood Therapeutics, Inc. $16.07 1
EUSA Pharma (US) LLC $15.50 1
Clovis Oncology, Inc. $15.39 1
Heron Therapeutics, Inc. $13.95 1

Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TODD ADAM GERSTEN

NPI 1962408047 · CMS profile ID 88583

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

WELLINGTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962408047?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TODD ADAM GERSTEN, NPI 1962408047, CMS profile ID 88583. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962408047?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). TODD ADAM GERSTEN, NPI 1962408047, CMS profile ID 88583. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962408047?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
TODD ADAM GERSTEN, NPI 1962408047, CMS profile ID 88583, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1962408047?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

200 matching records · $3,964.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 200 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 200.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARRAY BIOPHARMA INC $26.7303/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833183913 CMS
Lilly USA, LLC $26.7503/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818801559 CMS
Merck Sharp & Dohme Corporation $22.5003/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848598455 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.9803/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789112993 CMS
Bayer HealthCare Pharmaceuticals Inc. $12.0103/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789069529 CMS
AstraZeneca Pharmaceuticals LP $11.2603/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834343939 CMS
Celgene Corporation $20.3003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783681783 CMS
GENZYME CORPORATION $17.7303/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843517689 CMS
Amgen Inc. $21.0503/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825842879 CMS
Genentech USA, Inc. $19.9903/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835986277 CMS
Janssen Biotech, Inc. $7.9203/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788863693 CMS
EUSA Pharma (US) LLC $15.5003/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852885245 CMS
Karyopharm Therapeutics Inc. $18.1903/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845789313 CMS
PFIZER INC. $20.6703/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832638657 CMS
AstraZeneca Pharmaceuticals LP $15.2103/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834342979 CMS
E.R. Squibb & Sons, L.L.C. $0.3203/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783452061 CMS
MorphoSys, US Inc. $24.1903/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854733767 CMS
JAZZ PHARMACEUTICALS INC. $17.5002/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845624995 CMS
AstraZeneca Pharmaceuticals LP $20.0102/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834342127 CMS
E.R. Squibb & Sons, L.L.C. $16.6302/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783452049 CMS
E.R. Squibb & Sons, L.L.C. $0.3602/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783452051 CMS
E.R. Squibb & Sons, L.L.C. $15.9702/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783452047 CMS
Daiichi Sankyo Inc. $23.5102/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836262891 CMS
Novartis Pharmaceuticals Corporation $18.3602/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812690763 CMS
PFIZER INC. $13.8602/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832550125 CMS
Ipsen Biopharmaceuticals, Inc $18.1902/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841907067 CMS
Dova Pharmaceuticals $13.2602/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849748205 CMS
PFIZER INC. $11.1902/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832726201 CMS
Myriad Genetic Laboratories, Inc. $18.0702/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834560117 CMS
Incyte Corporation $22.1402/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835543615 CMS
Merck Sharp & Dohme Corporation $16.0002/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848408691 CMS
Kyowa Kirin, Inc. $23.4902/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852985033 CMS
PFIZER INC. $21.4002/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832552181 CMS
GENZYME CORPORATION $17.6102/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843517681 CMS
MorphoSys, US Inc. $12.9101/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854733793 CMS
Janssen Scientific Affairs, LLC $350.0001/27/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989020635 CMS
Janssen Biotech, Inc. $29.4801/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788863709 CMS
E.R. Squibb & Sons, L.L.C. $20.0101/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783452035 CMS
Heron Therapeutics, Inc. $13.9501/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781455767 CMS
Eisai Inc. $13.3201/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817812233 CMS
Lilly USA, LLC $26.7501/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818761941 CMS
GENZYME CORPORATION $16.6401/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843517673 CMS
Taiho Oncology, Inc. $22.4701/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843377393 CMS
Genentech USA, Inc. $16.0501/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835986265 CMS
Eisai Inc. $14.8701/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817812609 CMS
PFIZER INC. $20.4201/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832706481 CMS
Pharmacyclics LLC, An AbbVie Company $24.0701/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781010523 CMS
Celgene Corporation $16.9501/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783681779 CMS
Celgene Corporation $19.2701/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783681781 CMS
Dova Pharmaceuticals $13.1601/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849748203 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,810.60 270
PY2020 $3,902.21 203
PY2021 $3,964.79 200
PY2022 $4,613.90 248
PY2023 $5,196.26 259
PY2024 $5,259.94 251
PY2025 $5,529.44 256

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $404,044.23 552
PY2024 Principal investigator $164,517.02 28
PY2023 Principal investigator $613,998.34 87
PY2022 Principal investigator $850,123.27 63
PY2021 Principal investigator $605,575.32 92
PY2020 Principal investigator $284,690.72 129
PY2019 Principal investigator $435,198.17 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

552 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,000.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) No dispute reported 06/30/2026 1185540605
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638590
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638592
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638594
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638596
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638598
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638600
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638602
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638604
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638606
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638608
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638610
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638612
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638614
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638616
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638618
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638620
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638622
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638624
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638626
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638628
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638630
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638632
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638634
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638636
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638638
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638640
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638642
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638644
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638646
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638648
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638650
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638652
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638654
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638656
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638658
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638660
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638662
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638664
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638666
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638668
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638670
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638672
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638674
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638676
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638678
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638680
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638682
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638684
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638686
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638688
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638690
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638692
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638694
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638696
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638698
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638700
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638702
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638704
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638706
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638708
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638710
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638712
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638714
Principal investigator 1 Janssen Research & Development, LLC $2,600.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175324070
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175324320
Principal investigator 1 Janssen Research & Development, LLC $2,232.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329007
Principal investigator 1 Janssen Research & Development, LLC $500.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329121
Principal investigator 1 Janssen Research & Development, LLC $47.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175321110
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175322370
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175322840
Principal investigator 1 Janssen Research & Development, LLC $562.50 12/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175326210
Principal investigator 1 Janssen Research & Development, LLC $4,022.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175322237
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638459
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638461
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638463
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638465
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638467
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638469
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638471
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638473
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638475
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638477
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638479
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638481
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638483
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638485
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638487
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638489
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638491
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638493
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638495
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638497
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638499
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638501
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638503
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638505
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638507
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638509
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638511
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638513
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638515
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638517
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638519
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638521
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638523
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638525
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638527
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638529
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638531
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638533
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638535
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638537
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638539
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638541
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638543
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638545
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638547
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638549
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638551
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638554
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638556
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638558
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638560
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638562
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638564
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638566
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638568
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638570
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638572
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638574
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638576
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638578
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638580
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638582
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638584
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638586
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638588
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175325466
Principal investigator 1 Janssen Research & Development, LLC $3,818.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327029
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327233
Principal investigator 1 Janssen Research & Development, LLC $3,426.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327774
Principal investigator 1 Janssen Research & Development, LLC $170.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328837
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328898
Principal investigator 1 Janssen Research & Development, LLC $6,780.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327155
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175322832
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175324463
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328942
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175320793
Principal investigator 1 Janssen Research & Development, LLC $4,200.00 10/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175321205
Principal investigator 1 Janssen Research & Development, LLC $7,252.00 10/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328890
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639306
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639308
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639310
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639312
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639314
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639316
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639318
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639320
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639322
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639324
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639326
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639328
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639330
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639332
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639334
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639336
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639338
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639340
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639342
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639344
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639346
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639348
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639350
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639352
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639354
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639356
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639358
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639360
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639362
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639364
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639366
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639368
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639370
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639372
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639374
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639376
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639378
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639380
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639382
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639384
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639386
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639388
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639390
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639392
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639394
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639396
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639398
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639400
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639402
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639404
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639406
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639408
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639410
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639412
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639414
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639416
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639418
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639420
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639422
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 09/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175326336
Principal investigator 1 Astellas Pharma Global Development $354.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185988
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175328037
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 09/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329424
Principal investigator 1 Astellas Pharma Global Development $183.67 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185990
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639186
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639188
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639190
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639192
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639194
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639196
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639198
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639200
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639202
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639204
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639206
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639208
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639210
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639212
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639214
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639216
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639218
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639220
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639222
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639224
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639226
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639228
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639230
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639232
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639234
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639236
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639238
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639240
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639242
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639244
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639246
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639248
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639250
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639252
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639254
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639256
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639258
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639260
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639262
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639264
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639266
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639268
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639270
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639272
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639274
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639276
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639278
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639280
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639282
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639284
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639286
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639288
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639290
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639292
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639294
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639296
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639298
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639300
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639302
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639304
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175325594
Principal investigator 1 Janssen Research & Development, LLC $6,812.67 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327385
Principal investigator 1 Janssen Research & Development, LLC $20,500.00 08/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175322191
Principal investigator 1 Janssen Research & Development, LLC $6,517.33 08/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175324792
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 08/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175326480
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639062
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639064
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639066
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639068
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639070
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639072
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639074
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639076
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639078
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639080
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639082
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639084
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639086
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639088
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639090
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639092
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639094
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639096
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639098
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639100
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639102
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639104
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639106
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639108
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639110
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639112
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639114
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639116
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639118
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639120
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639122
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639124
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639126
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639128
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639130
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639132
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639134
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639136
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639138
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639140
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639142
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639144
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639146
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639148
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639150
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639152
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639154
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639156
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639158
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639160
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639162
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639164
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639166
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639168
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639170
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639172
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639174
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639176
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639178
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639180
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639182
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639184
Principal investigator 1 Astellas Pharma Global Development $250.00 07/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185952
Principal investigator 1 Astellas Pharma Global Development $3,987.67 07/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185954
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 07/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175326898
Principal investigator 1 Janssen Research & Development, LLC $17,000.00 07/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327569
Principal investigator 1 Janssen Research & Development, LLC $3,430.00 07/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329553
Principal investigator 1 Mirati Therapeutics, Inc. $1,151.26 07/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236530668
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638962
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638964
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638966
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638968
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638970
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638972
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638974
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638976
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638978
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638980
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638982
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638984
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638986
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638988
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638990
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638992
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638994
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638996
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638998
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639000
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639002
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639004
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639006
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639008
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639010
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639012
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639014
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639016
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639018
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639020
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639022
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639024
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639026
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639028
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639030
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639032
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639034
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639036
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639038
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639040
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639042
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639044
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639046
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639048
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639050
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639052
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639054
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639056
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639058
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639060
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 06/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175325750
Principal investigator 1 Janssen Research & Development, LLC $20,500.00 06/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175325793
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,350.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) No dispute reported 06/30/2026 1185540609
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638838
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638840
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638842
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638844
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638846
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638848
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638850
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638852
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638854
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638856
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638858
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638860
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638862
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638864
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638866
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638868
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638870
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638872
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638874
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638876
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638878
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638880
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638882
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638884
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638886
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638888
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638890
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638892
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638894
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638896
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638898
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638900
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638902
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638904
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638906
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638908
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638910
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638912
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638914
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638916
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638918
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638920
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638922
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638924
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638926
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638928
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638930
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638932
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638934
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638936
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638938
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638940
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638942
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638944
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638946
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638948
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638950
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638952
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638954
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638956
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638958
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638960
Principal investigator 1 Astellas Pharma Global Development $250.00 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185948
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,759.40 05/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185540601
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $82,334.84 05/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1235993987
Principal investigator 1 AstraZeneca Pharmaceuticals LP $39,415.14 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185540607
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638782
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638784
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638786
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638788
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638790
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638792
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638794
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638796
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638798
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638800
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638802
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638804
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638806
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638808
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638810
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638812
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638814
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638816
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638818
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638820
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638822
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638824
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638826
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638828
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638830
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638832
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638834
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638836
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185956
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185958
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185960
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185962
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185964
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185966
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185968
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185970
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185972
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185974
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185976
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185978
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185980
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185982
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185984
Principal investigator 1 Astellas Pharma Global Development $500.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185986
Principal investigator 1 Ipsen Bioscience Inc. $5,455.48 04/01/2025 Non-covered Recipient Entity
SARAH CANNON CANCER INSTITUTE AT HDH
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545043
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638716
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638718
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638720
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638722
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638724
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638726
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638728
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638730
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638732
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638734
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638736
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638738
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638740
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638742
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638744
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638746
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638748
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638750
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638752
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638754
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638756
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638758
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638760
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638762
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638764
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638766
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638768
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638770
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638772
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638774
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638776
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638778
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute West Palm Beach
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220638780
Principal investigator 1 Astellas Pharma Global Development $500.00 03/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185944
Principal investigator 1 Astellas Pharma Global Development $588.00 03/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185946
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,400.50 02/25/2025 Non-covered Recipient Entity
Florida Cancer Specialists
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1235997365
Principal investigator 1 Astellas Pharma Global Development $250.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185950
Principal investigator 1 Novartis Pharmaceuticals Corporation $325.00 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer No dispute reported 06/30/2026 1190305005
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,300.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer No dispute reported 06/30/2026 1190304463
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,305.95 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185540603